Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FDMT NASDAQ:MNPR NASDAQ:MOLN NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$11.52-0.9%$9.54$3.68▼$12.34$607.45M2.75987,576 shs984,974 shsMNPRMonopar Therapeutics$87.63-1.5%$61.66$29.18▼$105.00$596.15M1.52132,177 shs203,059 shsMOLNMolecular Partners$3.93+3.4%$4.05$3.41▼$5.36$153.42M1.076,604 shs3,886 shsTECXTectonic Therapeutic$31.03+1.0%$29.01$14.39▼$36.03$579.66M3.19126,887 shs79,987 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics-0.86%+19.25%+32.26%+23.47%+182.35%MNPRMonopar Therapeutics-1.53%+29.43%+39.94%+61.98%+174.53%MOLNMolecular Partners+3.42%+2.88%-2.96%-3.34%+6.50%TECXTectonic Therapeutic+1.01%+3.36%+3.47%+5.72%+52.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$11.52-0.9%$9.54$3.68▼$12.34$607.45M2.75987,576 shs984,974 shsMNPRMonopar Therapeutics$87.63-1.5%$61.66$29.18▼$105.00$596.15M1.52132,177 shs203,059 shsMOLNMolecular Partners$3.93+3.4%$4.05$3.41▼$5.36$153.42M1.076,604 shs3,886 shsTECXTectonic Therapeutic$31.03+1.0%$29.01$14.39▼$36.03$579.66M3.19126,887 shs79,987 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics-0.86%+19.25%+32.26%+23.47%+182.35%MNPRMonopar Therapeutics-1.53%+29.43%+39.94%+61.98%+174.53%MOLNMolecular Partners+3.42%+2.88%-2.96%-3.34%+6.50%TECXTectonic Therapeutic+1.01%+3.36%+3.47%+5.72%+52.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFDMT4D Molecular Therapeutics 2.67Moderate Buy$29.88159.33% UpsideMNPRMonopar Therapeutics 3.00Buy$107.9123.14% UpsideMOLNMolecular Partners 2.25Hold$8.38113.10% UpsideTECXTectonic Therapeutic 3.00Buy$79.40155.88% UpsideCurrent Analyst Ratings BreakdownLatest MOLN, FDMT, MNPR, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026MNPRMonopar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/2/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026TECXTectonic Therapeutic Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$76.00 ➝ $81.005/8/2026FDMT4D Molecular Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.004/22/2026MOLNMolecular Partners HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.004/21/2026MNPRMonopar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026TECXTectonic Therapeutic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026FDMT4D Molecular Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026TECXTectonic Therapeutic Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.004/10/2026MOLNMolecular Partners Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/30/2026FDMT4D Molecular Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $21.00(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFDMT4D Molecular Therapeutics$85.21M7.07N/AN/A$8.85 per share1.30MNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/AMOLNMolecular Partners$5.65M28.09N/AN/A$2.40 per share1.64TECXTectonic TherapeuticN/AN/AN/AN/A$13.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFDMT4D Molecular Therapeutics-$140.11M-$2.57N/AN/AN/A-182.34%-36.83%-32.55%8/10/2026 (Estimated)MNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)MOLNMolecular Partners-$74.41M-$1.94N/AN/AN/AN/A-66.62%-54.85%8/24/2026 (Estimated)TECXTectonic Therapeutic-$74.15M-$4.46N/AN/AN/AN/A-32.33%-30.92%8/6/2026 (Estimated)Latest MOLN, FDMT, MNPR, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/11/2026Q1 2026MOLNMolecular Partners-$0.4340-$0.45-$0.0160-$0.44N/AN/A5/7/2026Q1 2026FDMT4D Molecular Therapeutics-$0.97-$1.01-$0.04-$1.01$2.59 million$3.05 million5/7/2026Q1 2026TECXTectonic Therapeutic-$1.16-$1.34-$0.18-$1.34N/AN/A3/27/2026Q4 2025MNPRMonopar Therapeutics-$0.5123-$0.61-$0.0977-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFDMT4D Molecular TherapeuticsN/A9.349.34MNPRMonopar TherapeuticsN/A56.0456.04MOLNMolecular PartnersN/A9.439.43TECXTectonic TherapeuticN/A18.5118.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFDMT4D Molecular Therapeutics99.27%MNPRMonopar Therapeutics1.83%MOLNMolecular Partners26.55%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipFDMT4D Molecular Therapeutics7.90%MNPRMonopar Therapeutics9.70%MOLNMolecular Partners5.93%TECXTectonic Therapeutic39.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFDMT4D Molecular Therapeutics12052.28 million48.15 millionOptionableMNPRMonopar Therapeutics106.70 million6.05 millionNot OptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableTECXTectonic Therapeutic12018.87 million11.36 millionN/AMOLN, FDMT, MNPR, and TECX HeadlinesRecent News About These CompaniesTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Rating of "Buy" from BrokeragesJune 18, 2026 | americanbankingnews.comTectonic Therapeutic Completes Enrollment in Key TX45 TrialJune 10, 2026 | tipranks.comTectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF PatientsJune 10, 2026 | globenewswire.comTectonic Therapeutic Inc TECXMay 31, 2026 | morningstar.comMRaymond James upgrades Tectonic Therapeutic (TECX)May 27, 2026 | msn.comTectonic Therapeutics: Currently In A Catalyst VacuumMay 19, 2026 | seekingalpha.comLifeSci Capital Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)May 17, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)May 11, 2026 | theglobeandmail.comTectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comTectonic Therapeutic (NASDAQ:TECX) Insider Marcella Ruddy Sells 1,065 SharesMay 7, 2026 | insidertrades.comTectonic Therapeutic Appoints Jessica Chutter to Board of DirectorsApril 23, 2026 | globenewswire.comStifel initiates coverage of Tectonic Therapeutic (TECX) with buy recommendationApril 16, 2026 | msn.comTectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2April 16, 2026 | seekingalpha.comInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,000 Shares of StockApril 4, 2026 | insidertrades.comTectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLCMarch 15, 2026 | defenseworld.netDInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 6,262 Shares of StockMarch 10, 2026 | insidertrades.comTectonic Therapeutic Announces Leadership Transition and New ChairMarch 9, 2026 | theglobeandmail.comStocks showing market leadership: Tectonic Therapeutic earns 96 RS ratingMarch 9, 2026 | msn.comTectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference TranscriptMarch 6, 2026 | seekingalpha.comTectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,649 SharesMarch 6, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMOLN, FDMT, MNPR, and TECX Company Descriptions4D Molecular Therapeutics NASDAQ:FDMT$11.52 -0.10 (-0.86%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$11.06 -0.46 (-3.95%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Monopar Therapeutics NASDAQ:MNPR$87.63 -1.36 (-1.53%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$87.69 +0.06 (+0.07%) As of 06/25/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Molecular Partners NASDAQ:MOLN$3.93 +0.13 (+3.42%) Closing price 06/25/2026 03:59 PM EasternExtended Trading$3.92 -0.01 (-0.13%) As of 06/25/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Tectonic Therapeutic NASDAQ:TECX$31.03 +0.31 (+1.01%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$31.02 -0.02 (-0.05%) As of 06/25/2026 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal MDA Space Targets US Defense Market With $620M Acquisition Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat Cerebras Systems, Inc: The Next Rags-to-Riches AI Story? Domino's Stock Slides to 52-Week Low as Investors Digest CEO Change Getty Images’ OpenAI Deal Gives the Stock a New AI Licensing Story Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
